Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 13Breast 6Genitourinary 5Gastrointestinal 5Thoracic 4Head & Neck 3Sarcoma 2Lymphoid 2Dermatologic 2Plasma cell 1Other hematologic neoplasm 1CNS 1

Conditions

Leukemia, Myeloid, Acute 209Leukemia, Lymphocytic, Chronic, B-Cell 136Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Hematologic Neoplasms 114Myelodysplastic Syndromes 97Leukemia 82Lymphoma 65Lymphoma, Non-Hodgkin 57Multiple Myeloma 43Leukemia, Myelogenous, Chronic, BCR-ABL Positive 38Leukemia, Myelomonocytic, Chronic 36Neoplasms 31Recurrence 27Myeloproliferative Disorders 27Burkitt Lymphoma 25Lymphoma, Mantle-Cell 23Leukemia, Biphenotypic, Acute 23Lymphoma, Large B-Cell, Diffuse 22Lymphoma, Follicular 20Lymphoma, B-Cell, Marginal Zone 20Lymphoma, B-Cell 20Leukemia, Myeloid, Chronic-Phase 16Leukemia, B-Cell 16Hodgkin Disease 16Primary Myelofibrosis 15Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15Waldenstrom Macroglobulinemia 14Hematologic Diseases 14Anemia, Refractory, with Excess of Blasts 11Leukemia, Myeloid, Accelerated Phase 10

Interventions

ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Trastuzumab 1Sunitinib 1Specimen Handling 1PF-05280014 1Ontruzant 1Ogivri 1Nuclear Medicine Department, Hospital 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1HhAntag691 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Uterine Neoplasms × Other hematologic neoplasm × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡